Xencor (NASDAQ:XNCR – Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25), Briefing.com reports. The firm had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. The company’s revenue for the quarter was down 62.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.37) earnings per share.
Xencor Stock Performance
XNCR traded down $2.15 during trading hours on Wednesday, hitting $15.70. 1,072,853 shares of the stock were exchanged, compared to its average volume of 639,903. The stock has a market cap of $968.06 million, a price-to-earnings ratio of -7.21 and a beta of 0.69. The stock has a 50-day simple moving average of $20.25 and a 200-day simple moving average of $21.24. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.08 and a quick ratio of 7.08. Xencor has a 12 month low of $15.31 and a 12 month high of $26.84.
Insider Buying and Selling at Xencor
In other news, VP John R. Desjarlais sold 36,329 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total value of $665,547.28. Following the transaction, the vice president now directly owns 192,319 shares in the company, valued at approximately $3,523,284.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.23% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
View Our Latest Report on XNCR
About Xencor
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Further Reading
- Five stocks we like better than Xencor
- Want to Profit on the Downtrend? Downtrends, Explained.
- What Are Bonds? A High-Level Overview
- What is the Australian Securities Exchange (ASX)
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- How to Invest in Small Cap Stocks
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.